Symbols / SGMO Stock $0.15 -0.73% Sangamo Therapeutics, Inc.

Healthcare • Biotechnology • United States • OQB
SGMO (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Alexander D. Macrae Ch.B, M.B., MRCP,…
Exch · Country OQB · United States
Market Cap 61.69M
Enterprise Value 53.48M
Income -123.33M
Sales 34.56M
FCF (ttm) -48.58M
Book/sh -0.05
Cash/sh 0.07
Employees 142
Insider 10d —
IPO Apr 06, 2000
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 29.78
PEG —
P/S 1.79
P/B -3.24
P/C —
EV/EBITDA -0.50
EV/Sales 1.55
Quick Ratio 0.64
Current Ratio 0.70
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.38
EPS next Y 0.01
EPS Growth —
Revenue Growth -77.60%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-14
ROA -94.37%
ROE —
ROIC —
Gross Margin -227.67%
Oper. Margin -22.15%
Profit Margin 0.00%
Shs Outstand 414.29M
Shs Float 370.04M
Insider Own 1.76%
Instit Own 25.84%
Short Float 10.42%
Short Ratio 5.55
Short Interest 42.88M
52W High 0.77
vs 52W High -80.66%
52W Low 0.10
vs 52W Low 48.90%
Beta 1.29
Impl. Vol. 4.13%
Rel Volume 0.09
Avg Volume 9.89M
Volume 868.02K
Target (mean) $2.50
Tgt Median $2.00
Tgt Low $1.00
Tgt High $5.00
# Analysts 4
Recom Buy
Prev Close $0.15
Price $0.15
Change -0.73%
About

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. – ALS and Frontotemporal Lobar Degeneration; Takeda – Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$2.50
Mean price target
2. Current target
$0.15
Latest analyst target
3. DCF / Fair value
$-2.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.15
Low
$1.00
High
$5.00
Mean
$2.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-02-10 reit HC Wainwright & Co. Buy → Buy $10
2025-11-07 down Barclays Overweight → Equal-Weight $1
2025-09-04 reit HC Wainwright & Co. Buy → Buy $10
2025-06-24 reit HC Wainwright & Co. Buy → Buy $10
2025-05-14 main Barclays Overweight → Overweight $5
2025-04-07 reit HC Wainwright & Co. Buy → Buy $10
2025-03-18 reit RBC Capital Sector Perform → Sector Perform $2
2025-01-27 reit HC Wainwright & Co. Buy → Buy $10
2025-01-23 main Truist Securities Buy → Buy $5
2025-01-02 reit HC Wainwright & Co. Buy → Buy $10
2024-12-31 main Jefferies Buy → Buy $3
2024-12-31 main Wells Fargo Equal-Weight → Equal-Weight $2
2024-12-20 reit HC Wainwright & Co. Buy → Buy $10
2024-12-19 reit HC Wainwright & Co. Buy → Buy $10
2024-12-10 reit HC Wainwright & Co. Buy → Buy $10
2024-11-14 reit HC Wainwright & Co. Buy → Buy $10
2024-11-14 main Barclays Overweight → Overweight $9
2024-11-05 main HC Wainwright & Co. Buy → Buy $10
2024-10-23 reit HC Wainwright & Co. Buy → Buy $5
2024-10-22 reit HC Wainwright & Co. Buy → Buy $5
News
RSS: Latest SGMO news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-22 DAVIS GREGORY D Officer — 69,827 $0.25 $17,694
2026-04-21 DUBOIS-STRINGFELLOW NATHALIE Officer — 345,942 $0.26 $89,184
2025-06-12 PARKER H STEWART Director — 25,000 $0.00 $0
2025-06-12 MARKELS JOHN Director — 25,000 $0.00 $0
2025-06-12 HORN MARGARET A Director — 25,000 $0.00 $0
2025-06-12 MEYERS JAMES ROBERT Director — 25,000 $0.00 $0
2025-06-12 CAREY ROBERT F. Director — 25,000 $0.00 $0
2025-06-12 HILLAN KENNETH J. Director — 25,000 $0.00 $0
2025-06-12 SMITH KAREN LESLEY M.D. PH.D. Director — 25,000 $0.00 $0
2025-06-12 BEERS COURTNEY Director — 25,000 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
39.55
-31.57%
57.80
-67.20%
176.23
+58.34%
111.30
Operating Revenue
39.55
-31.57%
57.80
-67.20%
176.23
+58.34%
111.30
Operating Expense
147.56
-5.56%
156.25
-47.07%
295.22
-5.55%
312.58
Research And Development
112.67
+1.03%
111.52
-52.35%
234.06
-6.34%
249.90
Selling General And Administration
34.89
-22.00%
44.73
-26.88%
61.17
-2.42%
62.68
General And Administrative Expense
34.89
-22.00%
44.73
-26.88%
61.17
-2.42%
62.68
Other Gand A
34.89
-22.00%
44.73
-26.88%
61.17
-2.42%
62.68
Total Expenses
147.56
-5.56%
156.25
-47.07%
295.22
-5.55%
312.58
Operating Income
-108.00
-9.71%
-98.45
+17.27%
-118.99
+40.88%
-201.28
Total Operating Income As Reported
-121.24
-16.61%
-103.97
+62.06%
-274.00
-36.13%
-201.28
EBITDA
-100.40
-12.70%
-89.09
+7.97%
-96.80
+46.44%
-180.72
Normalized EBITDA
-87.17
-4.31%
-83.57
-243.55%
58.21
+132.21%
-180.72
Reconciled Depreciation
7.60
-18.79%
9.36
-57.82%
22.19
+7.93%
20.56
EBIT
-108.00
-9.71%
-98.45
+17.27%
-118.99
+40.88%
-201.28
Total Unusual Items
-13.23
-139.72%
-5.52
+96.44%
-155.01
0.00
Total Unusual Items Excluding Goodwill
-13.23
-139.72%
-5.52
+96.44%
-155.01
0.00
Special Income Charges
-13.23
-139.72%
-5.52
+96.44%
-155.01
0.00
Impairment Of Capital Assets
13.23
+139.72%
5.52
-96.44%
155.01
0.00
Net Income
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Pretax Income
-123.50
-25.88%
-98.11
+62.68%
-262.90
-37.04%
-191.85
Net Non Operating Interest Income Expense
1.30
-13.95%
1.51
-86.37%
11.10
+17.71%
9.43
Net Interest Income
1.30
-13.95%
1.51
-86.37%
11.10
+17.71%
9.43
Interest Income Non Operating
1.30
-13.95%
1.51
-86.37%
11.10
+17.71%
9.43
Interest Income
1.30
-13.95%
1.51
-86.37%
11.10
+17.71%
9.43
Other Income Expense
-16.80
-1332.05%
-1.17
+99.24%
-155.01
—
Other Non Operating Income Expenses
-3.56
-181.95%
4.35
—
—
Tax Provision
-0.57
-240.12%
-0.17
+96.71%
-5.07
-1282.28%
0.43
Tax Rate For Calcs
0.00
+193.77%
0.00
-91.18%
0.00
-90.81%
0.00
Tax Effect Of Unusual Items
-0.07
-604.15%
-0.01
+99.69%
-2.99
0.00
Net Income Including Noncontrolling Interests
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Net Income From Continuing Operation Net Minority Interest
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Net Income From Continuing And Discontinued Operation
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Net Income Continuous Operations
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Minority Interests
—
—
0.00
0.00
Normalized Income
-109.76
-18.75%
-92.43
+12.64%
-105.81
+44.97%
-192.28
Net Income Common Stockholders
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Diluted EPS
-0.44
+10.20%
-0.49
+66.89%
-1.48
-18.40%
-1.25
Basic EPS
-0.44
+10.20%
-0.49
+66.89%
-1.48
-18.40%
-1.25
Basic Average Shares
280.19
+38.92%
201.70
+15.62%
174.44
+13.02%
154.34
Diluted Average Shares
280.19
+38.92%
201.70
+15.62%
174.44
+13.02%
154.34
Diluted NI Availto Com Stockholders
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
59.74
-41.22%
101.64
-38.52%
165.32
-70.61%
562.51
Current Assets
35.83
-30.68%
51.69
-45.20%
94.33
-68.59%
300.33
Cash Cash Equivalents And Short Term Investments
20.95
-50.03%
41.92
-48.25%
81.00
-70.82%
277.63
Cash And Cash Equivalents
20.95
-50.03%
41.92
-7.27%
45.20
-55.00%
100.44
Other Short Term Investments
—
0.00
-100.00%
35.80
-79.80%
177.19
Receivables
10.51
+128.64%
4.60
+13.06%
4.07
-9.06%
4.47
Accounts Receivable
0.37
-29.47%
0.53
-43.01%
0.92
-74.90%
3.68
Taxes Receivable
10.14
+149.07%
4.07
+29.52%
3.14
—
Accrued Interest Receivable
—
—
0.40
-49.24%
0.79
Prepaid Assets
—
—
—
18.22
Other Current Assets
4.37
-15.57%
5.17
-44.11%
9.26
-49.19%
18.22
Total Non Current Assets
23.91
-52.12%
49.94
-29.65%
70.99
-72.92%
262.18
Net PPE
14.11
-59.41%
34.76
-34.26%
52.87
-57.89%
125.53
Gross PPE
56.32
-24.48%
74.57
-28.23%
103.91
-35.88%
162.06
Accumulated Depreciation
-42.21
-6.01%
-39.82
+22.00%
-51.05
-39.74%
-36.53
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
—
—
—
5.73
Construction In Progress
—
0.00
-100.00%
1.09
-92.64%
14.77
Other Properties
30.94
-32.89%
46.10
-32.60%
68.41
-38.37%
110.99
Leases
21.83
-12.40%
24.92
-16.39%
29.81
-2.50%
30.57
Goodwill And Other Intangible Assets
—
—
0.00
-100.00%
88.28
Goodwill
—
—
0.00
-100.00%
37.55
Other Intangible Assets
—
—
—
50.73
Investments And Advances
—
—
0.00
-100.00%
29.84
Non Current Accounts Receivable
8.94
-30.22%
12.81
-16.62%
15.36
—
Other Non Current Assets
0.87
-63.39%
2.38
-13.96%
2.77
-85.07%
18.52
Total Liabilities Net Minority Interest
74.01
-6.15%
78.86
-4.33%
82.43
-69.19%
267.55
Current Liabilities
42.47
-7.29%
45.80
-4.04%
47.73
-57.27%
111.71
Payables And Accrued Expenses
22.14
+14.34%
19.37
-43.41%
34.22
-0.23%
34.30
Payables
14.44
-6.77%
15.48
+1.48%
15.26
-31.93%
22.42
Accounts Payable
14.44
-6.77%
15.48
+1.48%
15.26
-31.93%
22.42
Current Accrued Expenses
7.71
+98.53%
3.88
-79.53%
18.96
+59.57%
11.88
Pensionand Other Post Retirement Benefit Plans Current
17.72
+21.63%
14.57
+63.37%
8.92
-58.53%
21.51
Current Debt And Capital Lease Obligation
1.70
-60.54%
4.31
-6.01%
4.59
+11.33%
4.12
Current Capital Lease Obligation
1.70
-60.54%
4.31
-6.01%
4.59
+11.33%
4.12
Current Deferred Liabilities
0.90
-88.10%
7.56
0.00
-100.00%
51.78
Current Deferred Revenue
0.90
-88.10%
7.56
0.00
-100.00%
51.78
Total Non Current Liabilities Net Minority Interest
31.55
-4.58%
33.06
-4.73%
34.70
-77.73%
155.84
Long Term Debt And Capital Lease Obligation
25.09
-4.42%
26.25
-21.67%
33.52
-14.03%
38.99
Long Term Capital Lease Obligation
25.09
-4.42%
26.25
-21.67%
33.52
-14.03%
38.99
Non Current Deferred Liabilities
5.87
+0.00%
5.87
0.00
-100.00%
115.65
Non Current Deferred Revenue
5.87
+0.00%
5.87
0.00
-100.00%
109.38
Non Current Deferred Taxes Liabilities
—
—
0.00
-100.00%
6.27
Other Non Current Liabilities
0.58
-37.83%
0.93
-21.40%
1.19
-1.66%
1.21
Stockholders Equity
-14.27
-162.66%
22.77
-72.53%
82.89
-71.90%
294.96
Common Stock Equity
-14.27
-162.66%
22.77
-72.53%
82.89
-71.90%
294.96
Capital Stock
3.51
+64.80%
2.13
+19.48%
1.78
+6.77%
1.67
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
350.69
+64.77%
212.84
+19.48%
178.13
+6.80%
166.79
Ordinary Shares Number
350.69
+64.77%
212.84
+19.48%
178.13
+6.80%
166.79
Additional Paid In Capital
1,610.94
+5.12%
1,532.49
+2.71%
1,492.08
+2.88%
1,450.24
Retained Earnings
-1,627.25
-8.17%
-1,504.32
-6.96%
-1,406.38
-22.45%
-1,148.55
Gains Losses Not Affecting Retained Earnings
-1.46
+80.56%
-7.53
-63.87%
-4.59
+45.32%
-8.40
Minority Interest
—
—
0.00
0.00
Other Equity Adjustments
-1.46
+80.56%
-7.53
-63.87%
-4.59
+45.32%
-8.40
Total Equity Gross Minority Interest
-14.27
-162.66%
22.77
-72.53%
82.89
-71.90%
294.96
Total Capitalization
-14.27
-162.66%
22.77
-72.53%
82.89
-71.90%
294.96
Working Capital
-6.64
-212.74%
5.89
-87.37%
46.60
-75.30%
188.62
Invested Capital
-14.27
-162.66%
22.77
-72.53%
82.89
-71.90%
294.96
Total Debt
26.80
-12.34%
30.57
-19.78%
38.10
-11.61%
43.11
Capital Lease Obligations
26.80
-12.34%
30.57
-19.78%
38.10
-11.61%
43.11
Net Tangible Assets
-14.27
-162.66%
22.77
-72.53%
82.89
-59.90%
206.68
Tangible Book Value
-14.27
-162.66%
22.77
-72.53%
82.89
-59.90%
206.68
Available For Sale Securities
—
—
—
—
Investmentin Financial Assets
—
—
0.00
-100.00%
29.84
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-97.21
-44.79%
-67.14
+70.14%
-224.84
-0.54%
-223.63
Cash Flow From Continuing Operating Activities
-97.21
-44.79%
-67.14
+70.14%
-224.84
-0.54%
-223.63
Net Income From Continuing Operations
-122.93
-25.52%
-97.94
+62.01%
-257.83
-34.09%
-192.28
Depreciation Amortization Depletion
7.60
-18.79%
9.36
-57.82%
22.19
+7.93%
20.56
Depreciation
7.60
-18.79%
9.36
-57.82%
22.19
+7.93%
20.56
Depreciation And Amortization
7.60
-18.79%
9.36
-57.82%
22.19
+7.93%
20.56
Other Non Cash Items
0.03
-43.86%
0.06
-94.91%
1.12
—
Stock Based Compensation
9.08
-26.68%
12.38
-54.75%
27.36
-13.55%
31.65
Asset Impairment Charge
13.23
+139.72%
5.52
-96.44%
155.01
0.00
Deferred Tax
—
0.00
+100.00%
-6.33
0.00
Deferred Income Tax
—
0.00
+100.00%
-6.33
0.00
Operating Gains Losses
—
-1.03
—
—
Gain Loss On Investment Securities
—
-1.03
—
—
Gain Loss On Sale Of PPE
—
—
—
0.00
Change In Working Capital
-4.22
-193.72%
4.51
+102.75%
-164.03
-99.27%
-82.32
Change In Receivables
0.15
-83.74%
0.95
+197.64%
-0.98
-151.64%
1.89
Changes In Account Receivables
0.15
-60.96%
0.40
-85.59%
2.75
+17.99%
2.33
Change In Prepaid Assets
0.83
-81.07%
4.38
-57.25%
10.26
+308.92%
-4.91
Change In Payables And Accrued Expense
5.85
+169.39%
-8.43
-18.66%
-7.10
-153.20%
13.35
Change In Accrued Expense
3.05
-46.84%
5.74
+145.26%
-12.69
—
Change In Payable
2.79
+119.72%
-14.17
-353.52%
5.59
—
Change In Account Payable
2.79
+119.72%
-14.17
-353.52%
5.59
—
Change In Other Working Capital
-6.66
-149.57%
13.43
+108.33%
-161.16
-78.29%
-90.39
Change In Other Current Liabilities
-4.40
+24.60%
-5.83
-15.36%
-5.06
-123.96%
-2.26
Investing Cash Flow
-0.10
-100.27%
37.52
-75.56%
153.53
+158.97%
59.28
Cash Flow From Continuing Investing Activities
-0.10
-100.27%
37.52
-75.56%
153.53
+158.97%
59.28
Net PPE Purchase And Sale
-0.10
+61.80%
-0.27
+98.74%
-21.16
-4.88%
-20.17
Purchase Of PPE
-0.10
+61.80%
-0.27
+98.74%
-21.16
-4.88%
-20.17
Capital Expenditure
-0.10
+61.80%
-0.27
+98.74%
-21.16
-4.88%
-20.17
Net Investment Purchase And Sale
0.00
-100.00%
35.84
-79.48%
174.69
+119.85%
79.46
Purchase Of Investment
—
0.00
+100.00%
-59.55
+78.53%
-277.39
Sale Of Investment
0.00
-100.00%
35.84
-84.70%
234.24
-34.36%
356.85
Net Business Purchase And Sale
—
—
0.00
0.00
Purchase Of Business
—
—
0.00
0.00
Net Other Investing Changes
—
1.95
—
—
Financing Cash Flow
70.75
+149.32%
28.38
+94.52%
14.59
-82.77%
84.66
Cash Flow From Continuing Financing Activities
70.75
+149.32%
28.38
+94.52%
14.59
-82.77%
84.66
Net Common Stock Issuance
73.67
+154.11%
28.99
+91.92%
15.11
-82.20%
84.87
Proceeds From Stock Option Exercised
0.34
+18.62%
0.29
-68.98%
0.94
-50.66%
1.90
Net Other Financing Charges
-3.26
-260.95%
-0.90
+37.78%
-1.45
+30.94%
-2.10
Changes In Cash
-26.56
-2045.48%
-1.24
+97.82%
-56.72
+28.81%
-79.68
Effect Of Exchange Rate Changes
4.09
+299.76%
-2.05
-238.10%
1.48
+18.26%
1.25
Beginning Cash Position
43.42
-7.04%
46.70
-54.19%
101.94
-43.48%
180.37
End Cash Position
20.95
-51.75%
43.42
-7.04%
46.70
-54.19%
101.94
Free Cash Flow
-97.31
-44.36%
-67.41
+72.60%
-246.00
-0.90%
-243.80
Amortization Of Securities
—
-0.27
+88.28%
-2.33
-87.52%
-1.24
Common Stock Issuance
73.67
+154.11%
28.99
+91.92%
15.11
-82.20%
84.87
Issuance Of Capital Stock
73.67
+154.11%
28.99
+91.92%
15.11
-82.20%
84.87
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category